{
  "source": "PubMed",
  "query": "grape skin",
  "title": "Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis.",
  "abstract": "The treatment of acute bacterial skin and skin structure infections (ABSSSI) usually involves intravenous (i.v.) antibiotics requiring hospitalisation and increasing hospital costs. Since 2014, dalbavancin is approved for ABSSSIs treatment. However, evidence of its health economic impact on the German healthcare system is still limited.",
  "publication_date": "2023-04-20",
  "journal": "Journal of infection and public health",
  "doi": "10.1016/j.jiph.2023.04.015"
}